Transdermal penetrant formulations containing cannabidiol
Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents.
1. A method of treating a patient with an ailment by applying a transdermal formulation to the skin of the patient, the transdermal formulation comprising the following components:
a. Cannabidiol at a concentration from 1% to 7%;
b. a phosphatidylcholine at a concentration from 4% to 15%;
c. glucose at a concentration from 0% to 3%;
d. benzyl alcohol at a concentration from 0.25% to 5%;
e. deionized water at a concentration from 10% to 75%;
f. safflower oil at a concentration from 1% to 20%;
g. oleic acid at a concentration from 0.2% to 7.5%;
h. stearic acid at a concentration from 0.1% to 7%; and
i. isopropyl palmitate at a concentration from 5% to 30%,
wherein the ailment is pain, seizures or Parkinson's disease and wherein all amounts are percent by weight relative to the total weight of said transdermal formulation (w/w).
2. The method of claim 1 , wherein the Cannabidiol is at a concentration from 1.5% to 6%.
3. The method of claim 1 , wherein the transdermal formulation further comprises one or more of a moisturizer, cream, oil or lotion.
4. The method of claim 1 , wherein the transdermal formulation further comprises a surfactant.
5. The method of claim 1 , wherein the transdermal formulation further comprises a nonionic detergent.
6. The method of claim 1 , wherein the transdermal further comprises a polar gelling agent.
7. The method of claim 1 , wherein the transdermal formulation further comprises an antioxidant.
8. The method of claim 1 , wherein the transdermal formulation further comprises one or more additional active agents to treat the pain, seizures or Parkinson's disease.
9. The method of claim 1 , wherein the transdermal formulation has a pH from 4-6.
10. The method of claim 1 , wherein the safflower oil comprises a linoleic acid.